BofA Cautious on Hospitals, Forecasts 2-4% EBITDA Headwind Over Next 5 Years
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Should l Buy ARDT?
Source: Benzinga
- Dismal Industry Outlook: BofA Securities forecasts a 2-4% annual EBITDA headwind for hospitals over the next five years due to cuts from the Reconciliation Bill and the expiration of enhanced exchange subsidies, negatively impacting revenue and margins.
- Increased Policy Risks: Analysts note that while some new state-directed payment programs may be approved, future policy changes could further suppress hospital profitability, particularly concerning Medicaid and exchange policies.
- Intensified Market Competition: With healthcare demand stabilizing, core demand for hospital services is expected to grow below the midpoint of long-term ranges in 2026, as policy changes may lead to lower-than-expected volume growth for hospitals.
- Shift in Investment Preferences: BofA favors post-acute care companies like Encompass Health due to their minimal exposure to upcoming cuts, anticipating higher visibility growth, which reflects a positive outlook on favorable industry dynamics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 9.410
Low
10.00
Averages
13.73
High
17.00
Current: 9.410
Low
10.00
Averages
13.73
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Lawsuit Background: Ardent Health is facing a securities class action lawsuit for failing to disclose its accounting practices regarding receivables, with allegations that it used a 180-day cliff, leading to a 33% stock price drop following disclosures in November 2025.
- Financial Impact: The lawsuit claims that after transitioning to a new accounting method in Q3 2025, Ardent was forced to slash revenue by $42.6 million, highlighting significant deficiencies in the company's financial transparency.
- Liability Reserves Spike: Ardent Health recorded a $54 million increase in professional liability reserves in November 2025, indicating inadequacies in handling claims related to lawsuits from 2019 to 2022, which has heightened investor concerns.
- Investor Alert: Hagens Berman advises investors that the lead plaintiff deadline is March 9, 2026, urging them to monitor the case's developments to protect their interests.
See More
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Ardent Health and certain officers, seeking damages for investors who purchased securities between July 18, 2024, and November 12, 2025, highlighting significant investor concerns regarding the company's financial transparency.
- Financial Misrepresentation Allegations: The complaint alleges that Ardent Health overstated its Q3 2025 revenue due to inadequate assessments of accounts receivable collectability following its transition to a new revenue accounting system, severely undermining investor confidence in the company's financial health.
- EBITDA Guidance Downgrade: The company's 2025 EBITDA guidance is claimed to be overstated, with a projected reduction of $57.5 million at the midpoint, approximately 9.6%, reflecting persistent industry-wide cost pressures and payer denials, which exacerbates investor worries about future profitability.
- Investor Action Call: Investors are encouraged to apply to be lead plaintiffs by March 9, 2026, to participate in potential recoveries, indicating that legal avenues provide a means for affected investors to recover losses while underscoring the demand for corporate governance and transparency.
See More

- Legal Investigation: Faruqi & Faruqi, LLP is investigating potential claims against Ardent Health, Inc., particularly for investors who purchased or acquired securities between July 18, 2024, and November 12, 2025, indicating possible legal liabilities for the company.
- Investor Rights Reminder: The firm reminds investors that March 9, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, a critical date for protecting investor legal rights.
- Market Impact: Ardent Health's stock price is affected by potential legal issues, leading to significant financial losses for investors and exacerbating the market's confidence crisis regarding the company.
- Legal Consultation Opportunity: Faruqi & Faruqi offers a direct contact opportunity for investors to discuss their legal rights with partner Josh Wilson by calling 877-247-4292 or 212-983-9330 (Ext. 1310), demonstrating the firm's commitment to investor rights.
See More
- Lawsuit Background: Levi & Korsinsky LLP has notified investors of Ardent Health, Inc. (NYSE: ARDT) regarding a class action lawsuit due to alleged securities fraud covering the period from July 18, 2024, to November 12, 2025, aimed at recovering losses for affected investors.
- False Statements: The complaint alleges that Ardent Health misrepresented its accounts receivable assessment framework, actually employing a 180-day cliff that inflated reported receivables and delayed loss recognition on uncollectible accounts, rendering its financial position materially misleading.
- Insurance Shortfall: Ardent Health failed to maintain adequate professional liability insurance to cover claims arising from operations, particularly in New Mexico where social inflationary pressures in medical malpractice cases have been increasing, exposing the company to significant financial risks.
- Investor Rights: Affected investors must request to be appointed as lead plaintiffs by March 9, 2026, with participation in the lawsuit at no cost, indicating a risk-free opportunity for investors to seek compensation.
See More
- Deadline for Claims: Investors must file lead plaintiff applications for the securities class action against Ardent Health by March 9, 2026, if they purchased the company's securities between July 18, 2024, and November 12, 2025, ensuring their right to participate in the lawsuit.
- Financial Disclosure Issues: On November 12, 2025, Ardent disclosed a $43 million decrease in Q3 revenue due to a transition to a new revenue accounting system and evaluations of historical collection trends, which has led to a significant decline in market confidence regarding the company's financial health.
- EBITDA Guidance Cut: The company lowered its 2025 EBITDA guidance to a midpoint of $575 million, down approximately 9.6% from the previous $625 million, reflecting persistent industry-wide cost pressures and payer denials, which could negatively impact investor return expectations.
- Stock Price Plunge: Following the financial disclosures, Ardent's stock price plummeted from $14.05 to $9.30 per share, a nearly 34% drop, indicating severe market concerns about the company's future profitability and stability.
See More
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Ardent Health, alleging securities fraud and unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by March 9, 2026.
- Significant Revenue Decline: Ardent reported a $43 million decrease in Q3 2025 revenue, primarily due to revised assessments of accounts receivable collectability following the transition to a new revenue accounting system, which raises concerns about the company's financial stability.
- EBITDA Guidance Cut: The company lowered its 2025 EBITDA guidance to between $530 million and $555 million, a reduction of approximately 9.6% from the previous range of $575 million to $625 million, reflecting persistent industry-wide cost pressures and payer denials.
- Stock Price Plummet: Following the negative news, Ardent's stock price fell by $4.75, or 33.81%, closing at $9.30 per share on November 13, 2025, indicating significant market concerns regarding the company's financial health.
See More




